Key facts
- It has raised $2.9M; the latest was Early Stage VC ($2.9M) in Mar 2026.
- Notable investors include High-Tech Gründerfonds, GCP Capital Partners, Die BrückenKöpfe, GIMIC Ventures, Meerkat Holding — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Skinuvita
- ·The full record, as it builds
Funding rounds
No funding rounds for Skinuvita are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Skinuvita
Provider of a home-based light therapy intended to treat skin conditions such as psoriasis and atopic dermatitis. The company offers the ability to receive medically supervised phototherapy treatments through an app, enabling users with a non-invasive, comfortable, and privacy-conscious alternative to traditional methods, enhancing accessibility and improving the quality of life for individuals with chronic skin conditions.
- Sector
- Healthcare
- HQ
- Bremen, Germany
- Founded
- 2021
- Employees
- 17
- Website
- skinuvita.de/
- Ownership
- Privately Held (backing)
Skinuvita doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Skinuvita shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Skinuvita in its N-PORT filings yet. We sweep new filings monthly.